Intuitive Surgical, Inc.

(NASDAQ Global Select)
Back to all articles
Somewhat Bullish +45

Are You Overpaying For Intuitive Surgical Stock Versus Its Rivals?

Earnings report AI-generated analysis

πŸ“Š Intuitive Surgical leads its healthcare peer group with faster growth and higher operating margins than all five rivals.

πŸ’° The stock trades at a premium 45.3x trailing earnings, more than double the valuation of rival Globus Medical.

πŸ”§ Approximately 85% of ISRG's revenue is recurring, driven by instrument sales for installed da Vinci systems.

πŸ“ˆ Total procedures grew 16% in fiscal Q2 2026 across nearly 13,000 installed systems worldwide.

πŸ‡ΊπŸ‡Έ U.S. procedure growth has slowed, with management citing changes in patient insurance coverage as a factor.

🎯 Management forecasts da Vinci procedure growth between 13.5% and 15.5% for fiscal 2026.

⚠️ The company plans to launch longer-lasting instruments in H1 2027, which will lower the cost per use for customers.

πŸ“‰ A da Vinci procedure growth rate below 13.5% would indicate a slowdown faster than management expects.

Bullish Signals
  • Intuitive Surgical grows faster and earns higher operating margins than any of its five healthcare rivals.
  • The company holds the highest P/E ratio in its peer group at 45.3x, reflecting strong investor confidence despite a recent stock decline.
  • ISRG generated $6.0 billion in revenue from Instruments and Accessories in fiscal 2025, accounting for the majority of total revenue.
  • Total procedures grew 16% in fiscal Q2 2026, demonstrating strong demand for its installed da Vinci systems.
Risk Factors
  • U.S. procedure growth has already slowed, driven by patients deferring elective procedures due to insurance coverage changes.
  • Management warns that if da Vinci procedure growth falls below 13.5% in 2026, the company is slowing faster than expected.
  • The upcoming launch of longer-lasting instruments in H1 2027 will reduce the cost per use for customers, potentially impacting revenue per procedure.
Full Analysis
Intuitive Surgical (ISRG) maintains its position as the market leader in its healthcare peer group, demonstrating superior growth and profitability metrics compared to five major rivals. The company trades at a premium valuation of 45.3 times trailing earnings, significantly higher than competitors like Globus Medical which trades at 18.8x, even after ISRG's stock declined over 10% in the past year. Intuitive achieves this premium by generating higher operating margins and faster revenue growth than any rival in the group. The company's business model relies heavily on recurring revenue from instruments sold for use with its installed da Vinci surgical systems. As of fiscal Q2 2026, ISRG had nearly 13,000 systems installed globally, contributing to a 16% quarter-over-quarter increase in total procedures. Approximately 85% of the company's revenue is classified as recurring, driven by the high volume of procedures performed on existing hardware. Despite its strong historical performance, Intuitive faces potential headwinds including slowing growth in the U.S. market and upcoming product changes. Management forecasts da Vinci procedure growth between 13.5% and 15.5% for fiscal 2026, but acknowledges that U.S. growth has decelerated, partly due to patient insurance coverage changes. Additionally, the company plans to launch longer-lasting instruments in the first half of 2027, which will reduce the cost per use for customers and could impact future revenue streams.